No single evidence-based treatment protocol has been established for CSBD. This accurately represents the current state of the science and requires no qualification. The multimodal biopsychosocial treatment approach that constitutes current standard practice adapts frameworks developed primarily for substance use disorders, sexual offending, and obsessive-compulsive disorder. These adaptations are clinically reasonable. They are not empirically validated as CSBD-specific treatments. The absence of an established evidence base reflects, in part, the historical absence of formal diagnostic recognition: without a recognized diagnostic category, CSBD-specific clinical trials have been difficult to fund, design, and publish.
Cognitive-behavioral therapy constitutes the most extensively described psychological approach, adapted from substance use disorder, sexual offending treatment, and OCD. Its application targets trigger identification, functional analysis of behavioral antecedents, cognitive restructuring of permissive cognitions, and relapse prevention planning. CBT should be represented as the most systematically described and logically grounded first-line psychological intervention — not as empirically validated in the way that CBT is validated for established diagnostic categories.
Dialectical Behavior Therapy has gained increasing clinical application, driven by recognition that compulsive sexual behavior frequently functions as a mood-regulation strategy for dysphoric states. Its inclusion in the treatment armamentarium reflects a conceptually important shift: from treating the sexual behavior toward treating the affect dysregulation the behavior is serving. For patients whose compulsive sexual behavior is primarily a coping mechanism for anxiety, shame, or loneliness — a substantial proportion of clinical presentations — DBT’s distress tolerance and emotion regulation skills address the psychological terrain that maintains the disorder.
Attachment-focused and insight-oriented approaches address maintenance factors operating below the behavioral surface: the relational models, the defensive functions of sexual behavior, and the early experiences that shaped the patient’s template for intimacy, shame, and self-regulation. The robust finding that secure attachment is markedly underrepresented in CSBD clinical populations — approximately 8% prevalence versus approximately 40% in non-affected controls — provides a strong logical basis for attachment-attentive formulation and intervention.
No pharmacological agent is approved specifically for CSBD by any major regulatory authority. Available interventions are applied by extrapolation from related conditions on the basis of mechanistic plausibility and limited study data. Opioid antagonists — naltrexone and nalmefene — have received the most clinical attention. The mechanistic rationale is coherent: mu-opioid receptor blockade in mesolimbic reward circuitry is hypothesized to reduce the rewarding and craving-associated aspects of compulsive sexual behavior, directly analogous to naltrexone’s mechanism in alcohol use disorder and gambling disorder. Clinical practice reasonably extrapolates from those evidence bases. This extrapolation should be represented honestly as such.
SSRIs are applied on the basis of their established efficacy in OCD and compulsive-spectrum conditions, with particular relevance in presentations with prominent obsessive phenomenology or co-occurring depressive and anxiety disorders. Anti-androgen agents are appropriate in forensic or treatment-resistant contexts with significant risk to others; their use in voluntary outpatient treatment without paraphilic features is generally not indicated as first-line, given the side-effect profile and the ethical dimensions of drive-suppressive intervention in non-forensic contexts.
In presentations with confirmed ADHD comorbidity — present in substantially elevated rates in CSBD populations — pharmacological management of the attentional disorder may be a prerequisite for effective behavioral intervention, by improving the inhibitory capacity that behavioral change protocols rely on.
The treatment-goal question in CSBD — abstinence versus controlled engagement — requires individualized formulation. Unlike gambling disorder, where abstinence from all gambling is a defensible and frequently pursued goal, CSBD treatment goals must accommodate the reality that healthy sexual functioning is itself a treatment objective. Goals typically center on resolving compulsive patterns rather than eliminating sexual behavior. Naltrexone dosing in CSBD is extrapolated from gambling disorder and alcohol use disorder evidence. Standard starting doses (50 mg/day) are reasonable; higher doses may be considered in consultation with available addiction psychiatry literature. LFT monitoring at standard addiction psychiatry thresholds is appropriate. Patients should be explicitly informed that naltrexone is being used off-label. Attachment security rate in CSBD clinical populations (approximately 8% secure) versus non-affected controls (approximately 40% secure) is among the most clinically significant findings in the CSBD research literature. Routine assessment of attachment style and relational history should be standard in CSBD formulation, not optional. Comorbidity in CSBD clinical samples is pervasive: mood disorders, anxiety disorders, substance use disorders, ADHD, and personality pathology (particularly Cluster B features) are substantially overrepresented. Treatment planning that addresses CSBD in isolation from comorbid conditions will routinely underperform.